KEDI Global Obesity Care Industry Top 2+ Index

Lululemon's Q1 2026 earnings release is scheduled for June 4, 2026, with analysts forecasting weak results following previous guidance. Earnings releases typically result in a >5% price impact, justifying a Medium importance, scheduled.

Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.

Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.

Life Time is scheduled to release its Q1 2026 financial results before market open on May 5, 2026. Importance is Medium as earnings releases typically result in price movements exceeding 5%, scheduled.

Amgen is scheduled to report its first quarter 2026 financial results after the market close on April 30, 2026, followed by a conference call with management, scheduled. High importance is estimated due to typical volatility surrounding earnings releases.

Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026. This is a recurring event with high potential for stock price impact (analysts estimate ≥10%) based on revenue, earnings per share, and future guidance. scheduled

First quarter 2026 earnings release and conference call scheduled for April 30, 2026. Analysts forecast a loss per share, reflecting charges from recent acquisitions, forecasted. High importance estimated as earnings typically drive significant price movement, scheduled.

Founder Chip Wilson sent a letter to shareholders on April 29, 2026, launching a proxy battle to elect three new independent directors, citing a loss of brand direction and significant shareholder value destruction. This event is estimated to have a >10% price impact due to management uncertainty.

Reported Q1 2026 total revenue of $15.3 billion and core EPS of $2.58 on 2026-04-29, beating analyst expectations.

Announced the discontinuation of the atuliflapon asthma program on 2026-04-29 after it failed a Phase 2 trial due to lack of efficacy.

On April 28, 2026, the U.S. FDA's CDER proposed to withdraw the approval for Amgen's drug Tavneos due to effectiveness and safety concerns. High importance is estimated as drug withdrawals significantly impact revenue and reputation.

Q1 2026 earnings and revenue missed analyst expectations on April 28, 2026. Net sales were $13.1B (-1% reported, -5% constant currency) and core EPS was $1.99 (-13% reported), primarily due to US generic competition for the drug Entresto. The stock price declined following the announcement.

Received U.S. FDA clearance and CE Mark approval for its next-generation Ultreon 3.0 Software, an AI-powered coronary imaging platform.

Received US FDA approval for Breztri Aerosphere for the maintenance treatment of asthma in patients aged 12 and older on 2026-04-28.

On April 28, 2026, the FDA announced Amgen's participation in a new proof-of-concept pilot for real-time clinical trials (RTCT) for Imdelltra. Low importance is estimated as this is a procedural pilot program.

Received US FDA approval for the Saphnelo Pen, a self-administered autoinjector for the treatment of systemic lupus erythematosus (SLE) on 2026-04-28.

On 2026-04-24, shareholders approved the 2026 Incentive Stock Program and Kevin Conroy was appointed to the Board of Directors, increasing the board size from twelve to thirteen members.

Announced positive phase 3a results for oral semaglutide in children with type 2 diabetes. Medium importance as it expands the market for a key drug, expected.